Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wolff, D; Schleuning, M; von Harsdorf, S; Bacher, U; Gerbitz, A; Stadler, M; Ayuk, F; Kiani, A; Schwerdtfeger, R; Vogelsang, GB; Kobbe, G; Gramatzki, M; Lawitschka, A; Mohty, M; Pavletic, SZ; Greinix, H; Holler, E.
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2011; 17(1): 1-17.
Doi: 10.1016/j.bbmt.2010.05.011
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is almost solely based on phase II trials or retrospective analyses. The consensus conference on clinical practice in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as well as to provide guidelines for daily clinical practice. Treatment modalities are the use of steroids and calcineurin inhibitors as well as immunomodulating modalities (photopheresis, mTOR-inhibitors, thalidomide, hydroxychloroquine, vitamin A analogs, clofazimine), and cytostatic agents (mycophenolate mofetil, methotrexate, cyclophosphamide, pentostatin). Recent reports showed some efficacy of rituximab, alemtuzumab, and etanercept in selected patients. Moreover, tyrosine kinase inihibitors such as imatinib came into the field because of their ability to interfere with the platelet-derived growth factor (PDGF-R) pathway involved in fibrosis. An other treatment option is low-dose thoracoabdominal irradiation. Although different treatment options are available, the "trial-and-error system" remains the only way to identify the drug effective in the individual patient, and valid biomarkers are eagerly needed to identify the likelihood of response to a drug in advance. Moreover, the sparse evidence for most treatment entities indicates the urgent need for systematic evaluation of second-line treatment options in cGVHD. 2011 American Society for Blood and Marrow Transplantation. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Chronic Disease -
- Drug Therapy - methods Drug Therapy - trends
- Fibrosis - drug therapy
- Graft vs Host Disease - drug therapy Graft vs Host Disease - pathology
- Humans -
- Individualized Medicine - methods
- Salvage Therapy -
- Find related publications in this database (Keywords)
- Allogeneic hematopoietic stem cell transplantation
- Chronic GVHD
- Bone marrow transplantation
- Immunosuppressive therapy